1.
Prevention of cardiovascular disease: plea for a rationale use of diet and lipid-lowering drugs.
2.
La sitagliptine dans le traitement du diabete de type 2: le point, cinq ans apres sa commercialisation. ; Sitagliptin in the treatment of type 2 diabetes: insights five years after...
Le medicament du mois. Bydureon: premier agoniste des recepteurs du GLP-1 en une injection hebdomadaire (exenatide a liberation prolongee). ; Bydureon: first once weekly GLP-1 rece...
Is it possible to claim or refute sputum eosinophils ≥ 3% in asthmatics with sufficient accuracy using biomarkers?
Le medicament du mois. Combinaison fixe ezetimibe-rosuvastatine (Myrosor(R)). ; Ezetimibe-rosuvastatin fixed-dose combination (Myrosor(R))
Le sevrage ultra-rapide des toxicomanes aux opiaciés sous anesthiésie géniérale: Résultats préliminaires du protocole Liègeois ; Ultra-Rapid Opiate Detoxification under general Ana...
Synthetic cathinones in Belgium: 2 case reports with different issues observed in the emergency room
3.
4.
5.
6.
7.
8.
9.
From point prevalence surveys to continuous quality improvement in a teaching hospital in Belgium
Meet the needs of elderly at primary care : Experience from Belgium
Quality control in drug distribution in Belgium